Tocilizumab was safe and effective for RA patients in comparison to tocilizumab plus DMARD therapy.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
October 28, 2014 2:46 AM
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapyVijay U. Rao MD, PhD1,†, Andrey Pavlov PhD2, Micki Klearman MD1,*, David Musselman MD1, Jon T. Giles MD, MPH3,Joan M. Bathon MD3, Naveed Sattar FRCPath, PhD4 andJanet S. Lee PhD5,‡
DOI: 10.1002/art.38920 Copyright © 2014 American College of Rheumatology Issue Arthritis & RheumatologyAccepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.) |
Krishan Maggon 's curator insight,
March 23, 2015 8:08 AM
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry Ryoko Sakai†, Soo-Kyung Cho†, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka, Masayoshi Harigai* and for the REAL Study Group *Corresponding author: Masayoshi Harigai mharigai.mpha@tmd.ac.jp † Equal contributors Author Affiliations For all author emails, please log on. Arthritis Research & Therapy 2015, 17:74 doi:10.1186/s13075-015-0583-8
Ryoko Sakai and Soo-Kyung Cho contributed equally to this work. Published: 23 March 2015 |
Clinical Rheumatology